GLOSSARY

Adipose Insulin Resistance is reduced adipose regulatory response to insulin.

Whole-body, liver, muscle and adipose insulin sensitivity are not one interchangeable measurement. Suppression of glucose production matters in liver, stimulation of uptake in muscle and suppression of lipolysis in adipose tissue. Resistance can differ between tissues and coexist with compensatory secretion. One fasting test without method and context cannot map the entire condition, and a postexercise change is not automatically evidence of disease or a need to eliminate carbohydrate.

Sensitivity is response to a given signal and is not identical to hormone concentration or receptor number. Receptor abundance, binding and downstream signaling can each alter response. Maximum responsiveness also differs from a shift in sensitivity. One blood value cannot describe all tissue receptors; assay type and target tissue are needed to interpret resistance or sensitivity rather than treating these as directly interchangeable concentration measurements.

Insulin is secreted by pancreatic beta cells and coordinates nutrient use and storage rather than simply being a fat-making hormone. Important effects include muscle and adipose glucose uptake, suppression of hepatic glucose production and regulation of lipolysis. Not every cell needs insulin for glucose entry. Postmeal concentrations vary with meal composition, tissue sensitivity and clearance, so one insulin excursion cannot determine overall dietary quality or an athlete's nutritional needs.

Muscle contraction can increase GLUT4 trafficking and glucose uptake through partly insulin-independent routes. Circulating insulin may decline during activity while muscle glucose use rises, so lower insulin does not universally imply lower glucose use. Recovery can also change sensitivity. Exercise type, surrounding meals and glucose-lowering medication alter interpretation; physiological changes in healthy exercise should not be transferred directly to medication management or disease without individualized clinical context.

Proinsulin processing produces insulin and C-peptide. C-peptide helps assess endogenous secretion but has different clearance from insulin, so concentrations and ratios need clinical context. Early and sustained secretion phases depend on stimulus and test method. One value cannot establish total beta-cell reserve, sensitivity across every tissue or medication need. Interpretation must distinguish secretion, precursor processing and removal rather than treating their biomarkers as identical measurements.

Hormonal imbalance is a broad description rather than a standalone diagnosis from an online symptom list. Deficiency, excess and resistance differ, and reference ranges depend on method, age and conditions. Medicines, illness, sleep and energy status also matter. Persistent symptoms need appropriate assessment to identify causes; choosing supplements or manipulating hormones from one isolated test cannot replace evidence-based evaluation or establish a universal athletic hormone target.